Population pharmacokinetic modeling and exposure-response analysis of anrikefon: insights and implications in clinical analgesia
Expert Review of Clinical Pharmacology · 2025
DOI: 10.1080/17512433.2025.2449983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Kun Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacometrics, Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China. Hauptthemen laut MEDLINE: Models, Biological, Postoperative Pain, Receptors, Opioid, kappa, Morphinans. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Haisco Pharmaceutical Group Co. Ltd.
Abstract (Originalsprache)
Background
Anrikefon (HSK21542), a potent and selective peripheral kappa opioid receptor (KOR) agonist developed by Haisco, effectively blocks pain and itch signals.
Aim
To develop a population pharmacokinetic (PK) model for anrikefon and conduct exposure-response (E-R) analysis for safety and efficacy in postoperative pain patients.
Method
The Population PK analysis uses NONMEM software with data from six trials. E-R relationships were assessed using safety and efficacy data from three trials. Covariate screening and Bayesian post-hoc simulations identified relevant factors and compared exposure metrics. The fixed dosing regimen was evaluated by simulation. Safety and efficacy endpoints were evaluated using logistic regression and Emax models.
Results
A three-compartment model with linear elimination accurately described anrikefon’s PK, incorporating weight through allometric scaling. Significant covariates affecting clearance included creatinine clearance, total bilirubin, albumin, aspartate transaminase, and age. Fixed and weight-based dosing showed similar exposures. No apparent E-R trend was observed for safety endpoints. The Emax model indicated that most of subjects achieved over 90% of the maximum effect for SPID0–24 h at 1.0 μg/kg. Safety analysis confirmed this dose was well tolerated with no safety issues.
Conclusion
This study provides valuable insights into dose selection, PK variability, and safety and efficacy endpoints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacometrics, Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China.
- Department of Clinical Pharmacology, Haisco Pharmaceutical Group Co. Ltd., Chengdu, China.
- Department of Medical Cosmetology, Hunan Provincial Hospital of Maternal and Child Health Care, Changsha, China.
Förderung
- Haisco Pharmaceutical Group Co. Ltd
Zitieren
APA
Wang, K., Chen, M., Xu, F., Zhang, F., Liu, L., Liu, X., Sun, Z., Zhao, W., Wang, Y., & Yang, J. (2025). Population pharmacokinetic modeling and exposure-response analysis of anrikefon: insights and implications in clinical analgesia. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2449983
Vancouver
Wang K, Chen M, Xu F, Zhang F, Liu L, Liu X, et al. Population pharmacokinetic modeling and exposure-response analysis of anrikefon: insights and implications in clinical analgesia. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2449983
BibTeX
@article{Wang2025,
author = {Wang, Kun and Chen, Meixia and Xu, Fengyan and Zhang, Fengyi and Liu, Lu and Liu, Xiao and Sun, Zhongyi and Zhao, Wanyun and Wang, Yongrui and Yang, Jing},
title = {Population pharmacokinetic modeling and exposure-response analysis of anrikefon: insights and implications in clinical analgesia},
journal = {Expert Review of Clinical Pharmacology},
year = {2025},
doi = {10.1080/17512433.2025.2449983}
}
EUVIMED